glp-1 wonder drug How weight-loss drugs are redefining the way our bodies work | Obesity GLP-1 drugs: the weight loss
Description
One article found an increased incidence of aspiration pneumonia among GLP-1 users compared to non-users reporting a hazard ratio of 1.33 (95%CI 1.021.74, p = 0.036) (Australian Diabetes Society, National Association of Clinical Obesity Services, Gastroenterological Society of Australia, and Australian and New Zealand College of Anaesthetists n.d.)
Their surging popularity has also revealed critical vulnerabilities in affordability and access
Multiple reviewers describe starting at very low doses (0.04 ml) and taking months to reach therapeutic levels, all while being charged $199-299/mo
Cardiovascular and renal outcomes with Efpeglenatide in type 2 diabetes
Wang, L., Berger, N
